Safety pharmacology of sibutramine mesylate, an anti-obesity drug

Human and Experimental Toxicology

Volumn 24, Issue 3, 2005, Pages 109-119

  Kim, Eun Joo ^a   Park, Eun Kyung ^a   Suh, Kwee Hyun ^b  

^a Korea Institute of Toxicology   (South Korea)

^b Hanmi Pharmaceutical Co Ltd   (South Korea)

Author keywords

Autonomic nervous system; Cardiovascular respiratory system; Central nervous system; General pharmacology; Sibutramine mesylate

Indexed keywords

ACETIC ACID; ANTIOBESITY AGENT; HEXOBARBITAL; MESYLIC ACID; PENTETRAZOLE; SIBUTRAMINE; STRYCHNINE;

ANALGESIA; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BEHAVIOR; BLOOD PRESSURE; BODY TEMPERATURE; BREATHING; BREATHING RATE; CARDIOVASCULAR SYSTEM; CENTRAL NERVOUS SYSTEM; CONVULSION; DOG; DOSE RESPONSE; DRUG EFFECT; DRUG SAFETY; ELECTRIC SHOCK; ELECTROCARDIOGRAM; FEMALE; HEART FUNCTION; HEART RATE; INTESTINE ABSORPTION; KIDNEY FUNCTION; LOCOMOTION; MALE; MOTOR COORDINATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; RESPIRATORY SYSTEM; SLEEP TIME; STOMACH PH; STOMACH SECRETION;

ADMINISTRATION, ORAL; ANIMALS; ANTI-OBESITY AGENTS; CYCLOBUTANES; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GASTRIC MUCOSA; GASTROINTESTINAL TRANSIT; GUINEA PIGS; MALE; MICE; MICE, INBRED ICR; MOTOR ACTIVITY; RATS; RATS, SPRAGUE-DAWLEY; RESPIRATION; SLEEP;

CANIS FAMILIARIS;

EID: 18044391464     PISSN: 09603271     EISSN: None     Source Type: Journal    
DOI: 10.1191/0960327105ht510oa     Document Type: Article

References (26)

1. World Health Organization. Obesity: Preventing and Managing the Global Epidemic. World Helth Organization: Geneva, 1998.
2. Pi-Sunyer FX. Medical hazards of obesity. Ann Int Med 1993; 119: 655-60.
3. Cheerthan SC, Viggers JA, Slater NA. Inhibition of [3H]-paroxetine binding by sibutramine, its metabolites and other antidepressants correlates with inhibition of [3H]-5-HT uptake. Br J Pharmacol 1990; 101 (Suppl.): 515 (Abstract).
4. Luscombe GP, Hopcroft RH, Thomas PC, Buckett WR. The contributrion of metabolites to the rapid and potent down-regulation of rat cortical beta-adrenoreceptors by the putative antidepressant sibutramine hydrochloride. Neuropharmacology 1989; 28: 129-34.
5. Stock MJ. Sibutramine: a review of the pharmacology of a novel anti-obesity agent. Int J Obes Relat Metab Disord 1997; 21 (Suppl. 1): S25-S29.
6. th edition. Abbott Park, IL: Abbott Laboratories, 2003: 475.
7. th edition, Merck & Co., Inc., 2001: 1522.
8. Reductil [package insert], Abbott Park, IL: Abbott Laboratories, 2000.
9. Irwin S. In Nodine JH, Siegler PE. Animal and clinical pharmacologic techniques in drug evaluation. Yearbook Medical Publishers: Chicago, 1964: 36-54.
10. Svensson TH, Thieme G. An investigation of a new instrument to measure motor activity of small animals. Psychopharmacologia (Berl) 1969; 14: 157-63.
11. Dunham WW, Miya TS. A note on a simple apparatus of detecting neurological deficit in rats and mice. J Am Pharm Ass 1957; 10: 208-10.
12. Koster R, Anderson M, De Beer EJ. Acetic acid for analgesic screening. Fed Proc 1959; 18: 412-18.
13. Swinyard EA, Brow WC, Goodman LS. Comparative assays of antiepileptic drugs in mice and rats. J Pharmacol Exp Therap 1952; 106: 319-30.
14. Woodbury LA, Davenport VD. Design and use of a new electroshock seizure apparatus, and analysis of factors altering seizure threshold and pattern. Arch Int Pharmacodyn 1592; 92: 97-107.
15. Miyazaki H, Tagawa M. Rate correction technique for QT interval in long term telemetry ECG recording in Beagle dogs. Exp Anim 2002; 51: 465-75.
16. Truett AA, West DB. Validation of a radiotelemetry system for continuous blood pressure and heart rate monitoring in dogs. Laboratory Animal Science 1995; 45: 299.
17. Trutt AA, Borne AT, Poincot MA, West DB. Autonomic control of blood pressure and heart rate in obese hypertensive dogs. Am J Physiology 1996; 270: R541.
18. Watts J, Maiorano L. Effects of diltiazem upon globally ischemic rat hearts. Eur J Pharmacol 1987; 138: 335-42.
19. Bolli R. Oxygen-derived free radicals and myocardial reperfusion injury: an overview. Cardiovasc Drugs Ther 1991; 5: 249-68.
20. Shay H, Komarov SA, Fels SS, Merange D, Gruenstein M, Siplet H. A simple method for the uniform production of gastric ulceration in rats. Gastroenterology 1945; 5: 43-61.
21. Lee JH, Park GS, Lee JC, Kim HK, Chang YK, Lee GS. The United States Patent Application Publication (Pub. No.: US 2004/0068018 A1), Apr. 8, 2004.
22. Astrup A, Hansen DL, Lundsgaard C, Toubro S. Sibutramine and energy balance. Int J Obes Rela Metab Disord 1998; 22: 30.
23. Meridia (sibutramine HCL monohydrate, anorexiant-antiobesity). In Compendium of Pharmaceuticals and Specialties, Ottawa: Canadian Pharmacist Association 2002: 980-84.
24. Luque CA, Rey JA. The discovery and status of sibutramine as an anti-obesity drug. Eur J Pharmacol 2002; 440: 119.
25. Bray GA, Blackburn GL, Ferguson JM. Sibutramine produces dose-related weight loss. Obesity Res 1999; 7: 189-98.
26. Van Gaal LF, De Wauters MA, Leew IH. Anti-obesity drugs; what does sibutramine offer? An analysis of its potential contribution to obesity treatment. Exp Clin Endocrinol Diabetes 1998; 106: 35-40.